<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979993/" ref="ordinalpos=1806&amp;ncbi_uid=6008779&amp;link_uid=PMC3979993" image-link="/pmc/articles/PMC3979993/figure/F5/" class="imagepopup">Figure 5.  From: Andrographolide Suppress Tumor Growth by Inhibiting TLR4/NF-?B <span class="highlight" style="background-color:">Signaling</span> Activation in Insulinoma. </a></div><br /><div class="p4l_captionBody"><b> Andro targets TLR4/NF-κB signaling in insulinoma. </b>Andro can significantly inhibited the protein expression of TLR4, MyD88, phosphorylated IκBα, p65, phosphorylated p65 (Ser536), and phosphorylated p65 (Ser276) of TLR4/NF-κB signaling pathway in tumor tissues of RIP1-Tag2 mice compared with control groups. Immunohistochemical staining showed that Andro also inhibited the expression of TLR4 (B), MyD88 (C) and p65 (D) in tumor tissues of RIP1-Tag2 mice compared with control groups. Bar, 20 μm. ***P &lt; 0.001.</div></div>